濾胞性甲状腺がん治療薬販売市場 - 世界の産業規模、シェア、動向、機会、予測、セグメント、タイプ別、エンドユーザー別、地域別、競合、2019年～2029年

世界の濾胞性甲状腺がん治療薬販売市場は、2023年に7億52万米ドルとなり、2029年までCAGR5.25％で予測期間に着実に成長すると予測されています。

甲状腺がんの亜型である濾胞性甲状腺がんは、甲状腺を侵す比較的まれではありますが重大な悪性腫瘍です。ここ数年、世界のヘルスケア情勢は、濾胞性甲状腺がんに対抗する効果的な薬剤の開発にますます焦点が当てられています。このため、世界の濾胞性甲状腺がん治療薬販売市場への関心が高まっています。世界の濾胞性甲状腺がん治療薬販売市場は、甲状腺がんの罹患率の上昇と製薬研究の進歩により、顕著な成長を遂げています。濾胞性甲状腺がんは、甲状腺乳頭がんに比べて甲状腺がん症例に占める割合は小さいですが、その攻撃的な性質から標的を絞った治療介入が必要です。濾胞性甲状腺がんの世界の有病率の増加は、薬剤開拓とそれに続く市場成長の重要な促進要因となっています。遺伝的素因、放射線被曝、ヨウ素欠乏などの要因が甲状腺がん症例の増加に寄与しています。

製薬会社は、より有効性が高く副作用の少ない新薬を発見するため、研究開発に多額の投資を行っています。このような進歩により、標的治療薬や免疫療法が採用され、濾胞性甲状腺がんの治療状況に変革をもたらしています。世界中の政府が甲状腺がんへの対応の重要性を認識し、この分野の研究開発を支援するイニシアチブを実施しています。資金調達、規制当局の支援、協力的な取り組みは、市場を前進させる重要な要因です。

主要な市場促進要因

罹患率の増加が世界の濾胞性甲状腺がん治療薬販売市場を牽引

政府の取り組みと支援が世界の濾胞性甲状腺がん治療薬販売市場を牽引

主要な市場課題

診断の遅れと誤診

主要な市場動向

技術の進歩

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（乳頭がん、濾胞がん、その他）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（202年）
• 市場マップ

第5章 アジア太平洋の濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの濾胞性甲状腺がん治療薬販売市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の濾胞性甲状腺がん治療薬販売市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• GlaxoSmithKline Plc
• Novartis AG
• Merck & Co
• Pfizer Inc
• Exelixis Inc
• Celgene Corporation
• Bayer AG
• Eisai Co., Ltd
• Teva Pharmaceuticals Industries Ltd.
• AstraZeneca Pharmaceuticals LP

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Follicular Thyroid Cancer Drug Sales Market was valued at USD 700.52 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Follicular thyroid cancer, a subtype of thyroid cancer, is a relatively rare but significant malignancy that affects the thyroid gland. Over the past few years, the global healthcare landscape has witnessed a growing focus on developing effective drugs to combat follicular thyroid cancer. This has led to an increased interest in the Global Follicular Thyroid Cancer Drug Sales Market. The global follicular thyroid cancer drug sales market has seen notable growth due to the rising incidence of thyroid cancer and advancements in pharmaceutical research. Follicular thyroid cancer accounts for a smaller percentage of thyroid cancer cases compared to papillary thyroid cancer, but its aggressive nature necessitates targeted therapeutic interventions. The increasing prevalence of follicular thyroid cancer worldwide has been a significant driver for drug development and subsequent market growth. Factors such as genetic predisposition, exposure to radiation, and iodine deficiency contribute to the rise in thyroid cancer cases.

Pharmaceutical companies are investing heavily in research and development to discover novel drugs with enhanced efficacy and fewer side effects. These advancements have resulted in the introduction of targeted therapies and immunotherapies that are transforming the treatment landscape for follicular thyroid cancer. Governments across the globe are recognizing the importance of addressing thyroid cancer and are implementing initiatives to support research and development in this field. Funding, regulatory support, and collaborative efforts are crucial factors propelling the market forward.

Key Market Drivers

Increasing Incidence Rates is Driving the Global Follicular Thyroid Cancer Drug Sales Market

Follicular thyroid cancer, a type of thyroid cancer that originates in the follicular cells of the thyroid gland, has witnessed a significant increase in incidence rates globally. This rise in cases has not only heightened concerns within the medical community but has also driven the market for follicular thyroid cancer drugs. As research and development efforts intensify, pharmaceutical companies are actively working to meet the growing demand for effective treatment options. In recent years, there has been a noticeable upward trend in the number of diagnosed cases of follicular thyroid cancer worldwide. Several factors contribute to this increase, including improved diagnostic techniques, increased awareness among both healthcare professionals and the general public, and a growing aging population. As early detection becomes more prevalent, the number of reported cases is expected to continue rising.

Advanced diagnostic technologies, such as ultrasound, fine-needle aspiration biopsy, and molecular testing, have greatly enhanced the ability to identify follicular thyroid cancer at earlier stages. This has led to increased detection rates, allowing medical professionals to diagnose and treat the disease more effectively. Consequently, the demand for pharmaceutical interventions has grown as clinicians seek improved treatment options for their patients. The aging global population is another factor contributing to the rise in follicular thyroid cancer cases. As individuals age, the risk of developing cancer, including thyroid cancer, tends to increase. The growing elderly demographic, particularly in developed countries, is a significant driver of the increasing incidence rates. The surge in follicular thyroid cancer cases has created a substantial market for pharmaceutical companies specializing in thyroid cancer treatments. These companies are investing heavily in research and development to bring innovative drugs to market, aiming to address the specific needs of patients with follicular thyroid cancer.

Government Initiatives and Support is Driving the Global Follicular Thyroid Cancer Drug Sales Market

Follicular thyroid cancer is a type of thyroid cancer that arises from the follicular cells of the thyroid gland. With an increasing incidence of thyroid cancer worldwide, the pharmaceutical industry has responded with the development of advanced drugs to combat follicular thyroid cancer. Government initiatives and support play a pivotal role in propelling the growth of the Global Follicular Thyroid Cancer Drug Sales Market, ensuring accessibility, affordability, and advancement in research and development. Governments across the globe recognize the significance of addressing thyroid cancer and have allocated substantial funds for research and development in this area. These funds are often directed towards supporting pharmaceutical companies, academic institutions, and research organizations engaged in the discovery and development of innovative drugs for follicular thyroid cancer. Research grants enable scientists and researchers to conduct clinical trials, invest in cutting-edge technologies, and explore novel therapeutic approaches. This financial backing accelerates the drug development process and fosters collaboration between the public and private sectors. Regulatory bodies, such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and similar agencies worldwide, play a crucial role in facilitating the approval process for new drugs. Governments work closely with these regulatory bodies to streamline procedures, ensuring that promising drugs for follicular thyroid cancer reach patients faster.

Fast-track designations, accelerated approvals, and orphan drug designations are some of the mechanisms governments use to expedite the availability of breakthrough drugs in the market. This not only benefits patients by providing earlier access to innovative treatments but also encourages pharmaceutical companies to invest in research and development for rare diseases like follicular thyroid cancer. Government initiatives extend beyond financial support to include the enhancement of healthcare infrastructure. Improved healthcare facilities and services contribute to early detection, diagnosis, and treatment of follicular thyroid cancer, ultimately driving the demand for associated drugs. Efforts to expand access to healthcare services, particularly in developing nations, have a direct impact on the global market for follicular thyroid cancer drugs. Increased awareness, regular screenings, and improved diagnostic capabilities are essential components of these initiatives.

Governments often collaborate with pharmaceutical companies to establish patient assistance programs. These programs aim to make expensive drugs more affordable for patients, ensuring that financial constraints do not impede access to life-saving treatments. Subsidies, co-payment assistance, and reimbursement schemes are implemented to alleviate the financial burden on individuals seeking follicular thyroid cancer drugs. In an era of global interconnectedness, governments are increasingly engaging in international collaborations for research and development. By fostering partnerships with other countries, governments can leverage diverse expertise, resources, and data to accelerate progress in the field of follicular thyroid cancer drug development.

Key Market Challenges

Diagnostic Delays and Misdiagnoses

One of the primary challenges faced by the global follicular thyroid cancer drug sales market is diagnostic delays. The symptoms of follicular thyroid cancer can be subtle and may overlap with other thyroid disorders, making accurate diagnosis a complex task. Common symptoms include fatigue, weight loss, changes in bowel habits, and a lump or swelling in the neck. These non-specific symptoms often lead to delays in seeking medical attention, resulting in a later-stage diagnosis. he diagnostic process itself can be time-consuming. Imaging studies, biopsy procedures, and pathology evaluations may take considerable time, especially in regions with limited healthcare infrastructure. The delay in diagnosing follicular thyroid cancer not only affects patient prognosis but also impacts the market dynamics by reducing the window for pharmaceutical companies to introduce their drugs during the early stages of the disease. In addition to diagnostic delays, misdiagnoses pose a significant challenge to the global follicular thyroid cancer drug sales market. Due to the similarities in symptoms with other thyroid conditions, there is a risk of misdiagnosing follicular thyroid cancer as a less severe thyroid disorder. Misdiagnoses can result in inappropriate treatment strategies, delaying the initiation of targeted therapies designed for follicular thyroid cancer.

The diagnostic challenges associated with follicular thyroid cancer have a direct impact on the sales of drugs developed for its treatment. Delayed diagnoses often mean that patients are diagnosed at advanced stages when the cancer has spread beyond the thyroid gland. In such cases, the effectiveness of available drugs diminishes, and the prognosis becomes less favorable. This not only affects patient outcomes but also limits the market potential for pharmaceutical companies.

Key Market Trends

Technological Advancements

In recent years, the field of healthcare has witnessed remarkable advancements, and one area that stands out is the treatment of Follicular Thyroid Cancer (FTC). The continuous evolution of technology has significantly contributed to the development of novel drugs and therapies, driving the Global Follicular Thyroid Cancer Drug Sales Market to new heights. Technological advancements have paved the way for a more personalized approach to cancer treatment, with precision medicine taking center stage. Understanding the genetic and molecular makeup of individual tumors allows for the development of targeted therapies that specifically address the characteristics of Follicular Thyroid Cancer. Molecular diagnostics and genomic profiling have become invaluable tools in identifying unique markers, enabling clinicians to tailor treatment plans to the specific needs of each patient.

The rise of immunotherapy has been a game-changer in cancer treatment, and FTC is no exception. Advanced technologies have led to the discovery and development of immunotherapeutic agents that harness the body's immune system to combat cancer cells. Checkpoint inhibitors, monoclonal antibodies, and other immunotherapies have shown promising results in clinical trials, offering new hope for patients with Follicular Thyroid Cancer resistant to traditional treatments. The integration of digital health technologies has facilitated remote monitoring and improved patient outcomes. Wearable devices, smartphone applications, and telemedicine platforms enable real-time tracking of patients undergoing FTC treatment. This not only enhances patient engagement but also provides healthcare professionals with valuable data for adjusting treatment plans and optimizing therapeutic outcomes. Big data analytics has revolutionized drug development by streamlining the identification of potential drug candidates and predicting their efficacy. By analyzing vast datasets encompassing genetic information, clinical trial results, and patient outcomes, researchers can expedite the drug discovery process. This has led to the accelerated development of innovative drugs for Follicular Thyroid Cancer, addressing the unmet medical needs of patients and contributing to the growth of the global market. Accurate diagnosis and monitoring of Follicular Thyroid Cancer heavily rely on imaging technologies. Innovations such as positron emission tomography (PET), magnetic resonance imaging (MRI), and ultrasound have improved the visualization of tumors, aiding in precise staging and treatment planning. These technological advancements not only enhance the efficiency of cancer management but also contribute to the overall growth of the FTC drug sales market.

Segmental Insights

Type Insights

Based on the category of type, Papillary Carcinoma emerged as the fastest growing segment in the global market for Follicular Thyroid Cancer Drug Sales in 2023. Papillary carcinoma has a higher prevalence and incidence rate compared to other subtypes of follicular thyroid cancer. The relatively higher frequency of papillary carcinoma cases contributes significantly to its dominance in the global market for thyroid cancer drugs. One of the key factors that distinguish papillary carcinoma is its generally favorable prognosis compared to other thyroid cancer subtypes. Patients with papillary carcinoma often have a higher survival rate, and the disease tends to progress more slowly. This characteristic makes it a prime focus for research and drug development efforts. Advances in diagnostic techniques have led to earlier and more accurate detection of papillary carcinoma. Improved screening methods, such as fine-needle aspiration biopsy and molecular testing, enable healthcare professionals to identify and diagnose papillary carcinoma at an early stage, facilitating timely intervention and treatment. The development of targeted therapies has played a crucial role in the dominance of papillary carcinoma in the thyroid cancer drug sales market. Researchers and pharmaceutical companies have focused on developing drugs that specifically target the molecular pathways associated with papillary carcinoma, leading to more effective and less toxic treatment options. Increased awareness among patients and healthcare professionals about the prevalence and characteristics of papillary carcinoma has contributed to its dominance. Patient advocacy groups and organizations play a crucial role in educating the public and healthcare providers, leading to early detection and intervention.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics offer comprehensive care to follicular thyroid cancer patients, from initial diagnosis to ongoing treatment and follow-up. This integrated approach ensures that patients receive a continuum of care, including drug therapy. As a result, these institutions become central hubs for the procurement and administration of follicular thyroid cancer drugs. Medical professionals in hospitals and clinics, including endocrinologists, oncologists, and specialized nursing staff, possess the expertise required for the proper management of follicular thyroid cancer. Their knowledge and experience play a critical role in prescribing and overseeing drug treatments, ensuring that patients receive optimal care. Hospitals and clinics are equipped with the necessary infrastructure for drug administration, including infusion centers for chemotherapy and facilities for radioactive iodine therapies. This ensures that patients can receive the prescribed drugs safely and effectively under the supervision of trained medical professionals.

Regional Insights

North America emerged as the dominant region in the global Follicular Thyroid Cancer Drug Sales market in 2023, holding the largest market share in terms of value. North America boasts a robust and advanced healthcare infrastructure, comprising cutting-edge research facilities, world-class medical institutions, and a well-established pharmaceutical industry. This advantageous ecosystem has played a pivotal role in positioning North America at the forefront of the global follicular thyroid cancer drug sales market. The pharmaceutical industry in North America has been a hub for innovation and research, consistently producing groundbreaking therapies and drugs. In the context of follicular thyroid cancer, North American pharmaceutical companies have been instrumental in developing and commercializing drugs that demonstrate efficacy in treating this specific type of cancer.

Key Market Players

• GlaxoSmithKline Plc
• Novartis AG
• Merck & Co
• Pfizer Inc
• Exelixis Inc
• Celgene Corporation
• Bayer AG
• Eisai Co., Ltd
• Teva Pharmaceuticals Industries Ltd.
• AstraZeneca Pharmaceuticals LP

Report Scope:

In this report, the Global Follicular Thyroid Cancer Drug Sales Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicular Thyroid Cancer Drug Sales Market, By Type:

• Papillary Carcinoma
• Follicular Carcinoma
• Others

Follicular Thyroid Cancer Drug Sales Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Follicular Thyroid Cancer Drug Sales Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Follicular Thyroid Cancer Drug Sales Market.

Available Customizations:

Global Follicular Thyroid Cancer Drug Sales market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Follicular Thyroid Cancer Drug Sales Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Papillary Carcinoma, Follicular Carcinoma, Others)
  • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2023)
• 4.3. Market Map

5. Asia Pacific Follicular Thyroid Cancer Drug Sales Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By End User
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Follicular Thyroid Cancer Drug Sales Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By End User
  • 5.3.2. India Follicular Thyroid Cancer Drug Sales Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By End User
  • 5.3.3. Australia Follicular Thyroid Cancer Drug Sales Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By End User
  • 5.3.4. Japan Follicular Thyroid Cancer Drug Sales Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By End User
  • 5.3.5. South Korea Follicular Thyroid Cancer Drug Sales Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By End User

6. Europe Follicular Thyroid Cancer Drug Sales Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Follicular Thyroid Cancer Drug Sales Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Germany Follicular Thyroid Cancer Drug Sales Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Spain Follicular Thyroid Cancer Drug Sales Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Italy Follicular Thyroid Cancer Drug Sales Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By End User
  • 6.3.5. United Kingdom Follicular Thyroid Cancer Drug Sales Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By End User

7. North America Follicular Thyroid Cancer Drug Sales Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Follicular Thyroid Cancer Drug Sales Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Mexico Follicular Thyroid Cancer Drug Sales Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Canada Follicular Thyroid Cancer Drug Sales Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End User

8. South America Follicular Thyroid Cancer Drug Sales Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Follicular Thyroid Cancer Drug Sales Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Argentina Follicular Thyroid Cancer Drug Sales Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Colombia Follicular Thyroid Cancer Drug Sales Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End User

9. Middle East and Africa Follicular Thyroid Cancer Drug Sales Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Follicular Thyroid Cancer Drug Sales Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Saudi Arabia Follicular Thyroid Cancer Drug Sales Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End User
  • 9.3.3. UAE Follicular Thyroid Cancer Drug Sales Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Follicular Thyroid Cancer Drug Sales Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. GlaxoSmithKline Plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Merck & Co
• 14.4. Pfizer Inc
• 14.5. Exelixis Inc
• 14.6. Celgene Corporation
• 14.7. Bayer AG
• 14.8. Eisai Co., Ltd
• 14.9. Teva Pharmaceuticals Industries Ltd.
• 14.10. AstraZeneca Pharmaceuticals LP

15. Strategic Recommendations

16. About Us & Disclaimer